Sparsh Strategic Consulting helps pharmaceutical, biotech, and medtech organisations achieve compliance, quality, and regulatory readiness, backed by 25+ years of global experience.
Clients typically call Sparsh when they need experienced, independent GxP quality judgement on matters that cannot be handled through internal process alone.
End-to-end GxP QA consulting, auditing, training, and strategic advisory for life sciences organisations worldwide.
Investigator site, pharmacovigilance, CSV, GDP, and for-cause audits. For sponsors, CROs, vendors, and clinical trial service providers.
Mock inspections, readiness assessments, and post-inspection response for FDA, EMA, MHRA, PMDA, NMPA, MFDS, and TFDA.
GCP training, inspection readiness, data integrity programmes, and CAPA implementation workshops tailored to your team.
Complex quality events, repeat findings, serious breaches, major deviations, RCA/CAPA review, and quality governance support.
GCP, GVP, GLP, GMP, CSV, GDP: QMS development, optimisation, vendor qualification, and strategic compliance advisory.
SaMD, digital health, and wearables quality integration. End-to-end clinical development strategy with a holistic patient safety perspective.
Tailored solutions across the life sciences spectrum, from multinational pharma to academic research institutions.
Sparsh Strategic Consulting was founded by Sachin Pasumamula, a GxP quality assurance professional with over 25 years of experience across pharmaceutical, biotech, medtech, and clinical development organisations on five continents.
Sachin has conducted and overseen GxP quality assurance engagements across 30+ countries and 5 continents, working directly with 12 health authorities including the FDA, EMA, PMDA, TGA, MHRA, NMPA, MFDS, Taiwan FDA, DCGI, HSA, Health Canada, and Anvisa.
He is the author of Quiet Watchdogs: GxP Quality Assurance, The Unsung Heroes Safeguarding Integrity Across the Drug Development Lifecycle (currently under publication) and the founder of SQIP, the Sparsh Quality Intelligence Platform, for which a patent was filed in Singapore in April 2026.
His approach combines deep regulatory knowledge with a genuine belief that quality is not a compliance exercise. It is the foundation of patient safety.
Ready to elevate your GxP compliance posture? Drop us a message and a Sparsh principal will respond within 24 hours.